Register
or
Sign in
to Save this opportunity, or Send an Inquiry.
You must be signed in to send an inquiry.
Please Register or Login to save this technology and benefit from all of Pharmalicensing's features.
Select to Save this to or Remove this from an Existing Collection
PON1 as a Detoxification Agent: Improved Anti-Atherosclerotic Activities for the Prevention of Restenosis
Yeda R&D Co. LtdIsrael
Abstract ID: 1475
The enzyme Paraoxonase 1 (PON1) resides on HDL in the blood. The levels of PON1 and its catalytic proficiency appear to have a major impact on susceptibility to
Send an Inquiry
Introduction/Background
The enzyme Paraoxonase 1 (PON1) resides on HDL in the blood. The levels of PON1 and its catalytic proficiency appear to have a major impact on susceptibility to atherosclerosis, cardiac and vascular diseases, cholesterol reducing drugs and various toxins and pollutants, such as organophosphates (pesticides and nerve gases). However, when trying to use the human PON1 one encounters several problems, including its insolubility and the lack of recombinant PON variants that can be expressed and manipulated in bacteria.
Aims/Hypothesis
There is a need for an enzyme with improved anti-atherosclerotic and detoxifying activities.
Results
PON1 resides within the cholesterol-carrying particles HDL and exhibits a multitude of activities related to the metabolism of drugs, lipids and other molecules associated with atherosclerotic vascular and cardiac diseases. The outlined technology utilized directed evolution in the laboratory, which yielded a series of variants that are 50-200 fold more proficient than native PON1 in different physiologically relevant tasks
Conclusion
The current technology offers new, genetically-engineered PON1 variants that are expressed in a fully functional form, at multi-milligram quantities and unprecedented purity.
Israel
MECHANISM
CLINICAL TRIALS
CORPORATION
